Opaganib: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 40: | Line 40: | ||
[[Category:Anticancer drugs]] | [[Category:Anticancer drugs]] | ||
[[Category:Antiviral drugs]] | [[Category:Antiviral drugs]] | ||
<gallery> | |||
File:Opaganib structure.png|Opaganib | |||
</gallery> | |||
Latest revision as of 01:11, 20 February 2025
An overview of the investigational drug Opaganib
Opaganib is an investigational drug that is being studied for its potential therapeutic effects in various medical conditions, including cancer and viral infections. It is a small molecule inhibitor that targets specific pathways involved in disease progression.
Mechanism of Action[edit]
Opaganib is known to inhibit the activity of sphingosine kinase-2 (SK2), an enzyme that plays a crucial role in the sphingolipid metabolic pathway. By inhibiting SK2, Opaganib reduces the production of sphingosine-1-phosphate (S1P), a lipid signaling molecule that is involved in cell proliferation, survival, and inflammation. This mechanism is thought to contribute to its potential anti-cancer and anti-inflammatory effects.
Therapeutic Applications[edit]
Cancer[edit]
Opaganib is being investigated for its use in treating various types of cancer, including prostate cancer, breast cancer, and glioblastoma. Its ability to inhibit SK2 and reduce S1P levels may help to slow down tumor growth and enhance the effectiveness of other cancer therapies.
Viral Infections[edit]
Research is also being conducted on the use of Opaganib in treating viral infections, such as COVID-19. The drug's anti-inflammatory properties and its ability to modulate immune responses make it a candidate for reducing the severity of viral infections.
Clinical Trials[edit]
Opaganib is currently undergoing clinical trials to evaluate its safety and efficacy in humans. These trials are essential for determining the appropriate dosing, potential side effects, and overall therapeutic value of the drug.
Side Effects[edit]
As with any investigational drug, Opaganib may have side effects. Commonly reported side effects in clinical trials include gastrointestinal disturbances, fatigue, and headache. The safety profile of Opaganib continues to be evaluated in ongoing studies.
Development and Research[edit]
Opaganib is being developed by RedHill Biopharma, a biopharmaceutical company focused on the development of novel therapeutics. The drug's development is part of a broader effort to explore new treatments for diseases with unmet medical needs.
Related pages[edit]
-
Opaganib
